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Abstract
Post-endoscopic retrograde cholangiopancreatography 
pancreatitis (PEP) is the most common complication 
of endoscopic retrograde cholangiopancreatography. 
The incidence of post-endoscopic retrograde cho-
langiopancreatography (ERCP) pancreatitis varies 
substantially and is reported around 1%-10%, although 
there are some reports with an incidence of around 
30%. Usually, PEP is a mild or moderate pancreatitis, 
but in some instances it can be severe and fatal. 
Generally, it is defined as the onset of new pancreatic-
type abdominal pain severe enough to require hospital 
admission or prolonged hospital stay with levels 
of serum amylase two to three times greater than 
normal, occurring 24 h after ERCP. Several methods 
have been adopted for preventing pancreatitis, 
such as pharmacological or endoscopic approaches. 
Regarding medical prevention, only non-steroidal 
anti-inflammatory drugs, namely diclofenac sodium 
and indomethacin, are recommended, but there are 
some other drugs which have some potential benefits 
in reducing the incidence of post-ERCP pancreatitis. 
Endoscopic preventive measures include cannulation 
(wire guided) and pancreatic stenting, while the 
adoption of the early pre-cut technique is still arguable. 
This review will attempt to present and discuss different 
ways of preventing post-ERCP pancreatitis.
Key words: Endoscopic retrograde cholangiopancrea-
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Core tip: Endoscopic retrograde cholangiopancrea-
tography (ERCP) is a widely used procedure for 
diagnosing and treating diseases of the pancreatobiliary 
tree. Post-ERCP pancreatitis is the most frequent 
complication. Prophylactic measures of post-endoscopic 
pancreatitis include pharmacological and mechanical 
ERCP related approaches. Prevention is suboptimal and 
still not widely accepted.
Hauser G, Milosevic M, Stimac D, Zerem E, Jovanović P, 
Blazevic I. Preventing post-endoscopic retrograde cholan-
giopancreatography pancreatitis: What can be done? World J 
Gastroenterol 2015; 21(4): 1069-1080  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i4/1069.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v21.i4.1069
INTRODUCTION
Endoscopic retrograde cholangiopancreatography 
(ERCP) is a widely used procedure for diagnosing 
and treating diseases of the pancreatobiliary tree, 
with over 500000 ERCP procedures performed 
annually in the United States alone[1]. Most common 
complications of ERCP are hemorrhage, pancreatitis, 
cholangitis and perforation, with pancreatitis after 
ERCP, or post-endoscopic pancreatitis (PEP) being 
the most frequent complication. The incidence of 
post-ERCP pancreatitis varies substantially and is 
reported to be around 1%-10%, although there are 
some reports with an incidence of around 30%[2,3]. 
Usually, it is a mild or moderate pancreatitis, but 
in some instances it can be severe and fatal[2]. 
According to a consensus from 1991, PEP is the 
presence of new pancreatic-type abdominal pain 
severe enough to require hospital admission or 
prolonged hospital stay with levels of serum amy-
lase two to three times greater than normal, 
occurring 24 h after ERCP[4,5]. Although PEP is mostly 
a mild complication of ERCP, it causes prolonged 
hospitalization, anatomical complications, and 
further procedures (endoscopies, laparoscopies, 
open surgery, etc.). It can cause the deterioration 
of the patient’s health, as well as a huge financial 
burden to hospitals. Therefore, preventing PEP 
could benefit both patients and hospitals. Attempts 
at preventing PEP have been carried out using 
pharmacological prophylaxis, technical measures or 
proper patient selection.
Prophylactic measures of PEP include phar-
macological and mechanical ERCP-related ap-
proaches. Mechanical solutions for PEP prevention 
have been found in prophylactic stenting of the 
pancreatic duct in high risk patients and early 
pre-cut cannulation. As a current gold standard, 
placement of a pancreatic stent is recommended. 
Nevertheless, endoscopists are looking for a ph-
armacological solution which will be safe, cheap, 
easily administered just before the procedure and 
applicable to all types of patients requiring ERCP.
In this review, we attempt to present and discuss 
different ways of preventing post-ERCP pancreatitis 
by reviewing the literature that describes various 
factors of PEP prevention and the possible utilization 
of endoscopic techniques and drugs in preventing 
PEP or lowering its incidence and severity. 
PHARMACOLOGICAL PREVENTION
Many pharmacological agents have been considered 
in the prevention of PEP, although their effectiveness 
remains debatable. These include allopurinol, gabexate 
mesylate, octreotide, somatostatin, antibiotics, non-
steroidal anti-inflammatory drugs (NSAIDs) and many 
others. The current literature reveals that basically all 
of the suggested pharmacological agents have either 
disappointing or inconclusive results so far, with the 
exception of NSAIDs[2,3,6-9].
Nitrates
Some potential in the prevention of PEP has been 
observed for glyceryl nitrate (GTN). Due to his 
dilatatore properties, it is believed that its usage 
could relax biliary and pancreatic sphincters, thus 
alleviating cannulation of the common bile duct 
(CBD). GTN can reduce the pressure of the sphincter 
of Oddi[10]. If used during and after ERCP, GTN can 
relax pancreatobiliary sphincters, facilitating CBD 
cannulation and reducing the chances of obstruction 
of the pancreatic outflow. GTN is also cost effective 
and easily administered. A meta-analysis was 
conducted exploring the aforementioned effects of 
GTN. More precisely, Chen et al[11] investigated the 
effect of prophylactic administration of GTN on the 
incidence of PEP, and the success of cannulation 
of the CBD duct. They conducted the analysis on 
a total number of 1841 patients. Out of the total 
number, 150 patients developed PEP; 55 were 
given GTN and 95 were given a placebo. They 
found a statistically significant difference in risk 
for acquiring PEP between the group who received 
GTN and the placebo group. They also analyzed 
the route of administration of GTN, and found that 
there were 10/128 patients (7.8%) who developed 
PEP after sublingual administration of GTN in 
comparison to 26/132 patients in the placebo 
group. On the other hand, transdermal application 
of GTN was less successful, and PEP developed in 
32/626 (5.1%) patients, whereas 50/640 (7.8%) 
patients in the placebo group acquired PEP. They 
concluded that sublingual administration of GTN 
had a better success rate in prevention of PEP. The 
second aim of their analysis was to determine if 
GTN contributes to a more successful cannulation. 
They found five and seven articles with 900 and 
1294 patients, respectively, in which they did 
not find any significant differences, meaning that 
prophylactic administration of GTN has no effect 
on facilitating bile duct cannulation. Wehrmann et 
al[12] also concluded that there was no difference 
between a group which received GTN and a group 
which received placebo in time needed for successful 
cannulation and the number of cannulation attempts.
They concluded that topical administration of GTN 
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does not alleviate cannulation of the bile duct during 
ERCP. The only adverse effects worth mentioning 
were hypotension and headache, both easily treated 
with intravenous administration of crystalloids. 
Chen et al[11] concluded: (1) GTN administration can 
prevent PEP and reduce its incidence; (2) GTN does 
not facilitate cannulation of the CBD; and (3) GTN is 
effective, cheap and easily administered.
There are other conflicting findings regarding the 
efficacy of GTN in PEP prophylaxis. Kaffes et al[13] 
conducted a prospective, double-blind, placebo-
controlled trial in which they evaluated the effect 
of GTN on the prevention of PEP and success rates 
of cannulation during ERCP. They included a total 
number of 318 patients divided into two groups-
one on a GTN transdermal patch (155 patients) and 
the other receiving placebo. There was no notable 
distinction between the two groups considering the 
success of initial cannulation, deep cannulation, time 
needed to achieve successful cannulation, usage of 
the needle knife or guide wire and PEP. Following 
their results, they concluded that transdermal 
GTN had no effect on the prevention of PEP or 
improvements in cannulation success rates. On the 
other hand, Bai et al[14] performed a meta-analysis 
of randomized, double-blind, placebo controlled 
trials evaluating the prophylactic properties of GTN 
in PEP prevention. They analyzed eight studies 
with a total of 1920 patients and found that GTN 
treatment significantly lowered the incidence rate of 
PEP; incidence of PEP in the GTN group and placebo 
group was 5.9% and 9.8%, respectively. Also, 
patients who received GTN had a 39% less chance 
of acquiring PEP.
Another, similar meta-analysis was performed 
by Ding et al[15].They included 12 randomized, 
controlled trials with 2649 patients; 11 of those trials 
reported the occurrence of PEP and compared 
GTN’s and placebo’s effect on PEP prevention. The 
results showed an overall incidence of PEP of 8.8% 
with a PEP incidence of 7.1% and 10.5% among 
GTN and placebo patients, respectively. They also 
conducted a sub-group meta-analysis comparing 
transdermal and sublingual application of GTN with 
the results suggesting that sublingual administration 
of GTN had far more success in prevention of PEP. 
In conclusion, their results indicated that GTN 
administration is an effective prophylactic measure 
in the prevention of PEP. An interesting approach 
has been made by a group of Iranian authors. 
Sotoudehmanesh et al[16] conducted a randomized 
trial with a combination of sublingual nitrates and 
indomethacin vs indomethacin alone as a method of 
preventing PEP. They reported RR = 0.39, 95%CI: 
0.18-0.96, P = 0.016, favoring the combination 
therapy. Drug-induced adverse events were equal 
among the study groups. They suggested that 
the aforementioned combination of drugs is more 
effective in reducing PEP incidence than indomethacin 
by itself. In conclusion, GTN is not recommended 
for routine use in PEP prophylaxis but GTN in com-
bination with some other agent such as NSAIDs 
may further reduce PEP incidence. Further research 
is needed in order to confirm and support these 
findings.
Heparin
A group of Chinese authors[17] performed a review 
and a meta-analysis of clinical trials on the potential 
beneficial properties of low-dose heparin in the 
prevention of PEP. Heparin has proven beneficial 
effects in acute pancreatitis in animals. Low-
molecular-weight heparin (LMWH) promotes the 
survival rate and decreases mortality in cases of 
severe acute pancreatitis. It also reduces the severity 
of pancreatitis related microcirculatory disorders in 
rats. In combination with insulin, heparin is beneficial 
in acute hyperlipidemic pancreatitis. However, there 
is conflicting data about its prophylactic effect. In 
their review Li et al[17] analyzed seven studies with 
a total number of 1438 patients. The incidence 
of PEP was 5.65% in the group which was given 
heparin and 7.91% in the control group. Severe 
PEP occurred in eight cases; 2/562 (0.35%) in the 
heparin group and 6/872 (0.69%) in the control 
group. Post-ERCP hemorrhage occurred in 23 
patients; 8/562 (1.42%) in the heparin group, and 
15/872 (1.72%) in the control group. These results 
showed no significant correlation between the use 
of heparin and reduction inPEP incidence. There was 
no connection between the use of heparin and post-
ERCP hemorrhage; low doses did not worsen post-
ERCP hemorrhage. They also compared low dose 
unfractioned heparin and low dose LMWH, finding no 
difference in the success of PEP reduction, reduction 
in the severity of PEP, or hemorrhage complications 
after ERCP. However, Rabenstein et al[18] produced 
results showing significant success in lowering PEP 
incidence in patients using heparin. They conducted 
an analysis on 815 patients that underwent ERCP 
and sphincterotomy. Heparin was given to 268 
patients, while the rest of the patients, precisely 547 
of them formed the control group. The incidence 
sof PEP were 3.4% and 7.9%, in the heparin group 
and the control group, respectively. Furthermore, 
heparin did not increase hemorrhagic complications. 
Based on their findings, they concluded that heparin 
administration correlated with a significantly lower 
incidence of PEP.
Ung et al[19] also conducted a randomized, double-
blind, placebo-controlled trial over 89 patients. They 
were randomly given either 0.2 mL of 25000 IE 
of heparin or 0.2 mL of saline subcutaneously 4 h 
before and 4 and 18 h after ERCP. They found that 
patients which were given heparin had no elevations 
in levels of amylase, ALT and AST. They concluded 
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or placebo, drop in oxygen saturation, or inability 
to reach the papilla, were excluded from the study. 
Cannulation of the common bile duct was performed 
by a sphincterotome. If unsuccessful after 5 min, 
a guide wire was used. In cases where guide wire 
cannulation failed after 5 min, pre-cut papillotomy 
was performed. A sphincterotome with guide wire 
cannulation time over 5 min was deemed difficult 
cannulation. They defined PEP according to the 
consensus from 1991[4]. PEP was graded as “mild” 
if lasting 3 d, “moderate” if therapeutic measures 
were required for 4 to 10 d after ERCP and “severe” 
if complications lasted longer than 10 d or if death 
occurred. Also, PEP was severe if a CT scan showed 
the presence of tissue necrosis in > 30% of the 
pancreas or if it showed peripancreatic fluid.
The aims of this study were to determine whe-
ther the aforementioned combination of drugs 
could prevent PEP and affect the type of PEP and 
side effects caused by the same combination[21]. 
The advantage of this study was that both groups 
were comparable in sex, age, indications for the-
rapeutic ERCP and ERCP findings. Also, there was 
no significant difference in cannulation difficulty, 
pancreatic opacification, number of guide wires 
inserted, and use of pre-cut papillotomy.
After data analysis, the overall PEP inciden-
ce was 7.2%, occurring in 39 patients. Mild PEP 
occurred in 29 patients (5.6%), moderate in 8 
(1.5%) and severe PEP in 2 patients (0.4%). They 
found a significant difference between the two 
groups in the rate of PEP: 4.7% in group A and 
10.4% in group B. Moreover, the incidence of PEP 
in high risk patients was significantly lower in the 
group receiving the diclofenac and somatostatin 
combination than in the placebo group, i.e., 5.8% 
and 12.3%, respectively. However, there was no 
significant distinction in low risk patients (group A 
1.5% and group B 3.5%). Based on univariate and 
multivariate analyses, they found that a history of 
acute pancreatitis, pancreatic opacification of the 
first class branches and beyond, and the absence 
of pharmacoprophylaxis were all independent risk 
factors for PEP development. Several problems arose 
in this study. It was difficult to differentiate patients 
with high and low risk for PEP. There are patient-
related factors such as suspected dysfunction of the 
sphincter of Oddi and previous acute pancreatitis 
which can be easily identified prior to the procedure. 
However, ERPC-related risk factors such as difficult 
cannulation, opacification of the pancreatic duct 
and pre-cut papillotomy can be identified only 
during and after ERCP. Logic therefore infers that 
an ideal pharmacoprophylactic agent has to include 
all patients undergoing ERCP. Further limitations 
to this study were the low number of pancreatic 
sphincterotomes, and only a few suspected sph-
incters of Oddi dysfunctions (SOD), which are 
that heparin reduces the increase in amylase levels 
which is typical for PEP. Li et al[17] concluded that 
neither low dose unfractioned heparin nor LMWH had 
a significant impact on reducing PEP incidence or its 
prevention. Despite some promising results where 
the beneficial effects of heparin were emphasized, 
this is still not a recommended prevention method. 
In addition to GTN and heparin, there are several 
other potential chemoprophylactic agents considered 
to be beneficial in the prevention of PEP.
Somatostatin and protease inhibitors
Somatostatin is a drug considered to have a 
beneficial effect on PEP prevention. It inhibits the 
secretory functions of the pancreas. It can also 
restrain the motility of the sphincter of Oddi. This 
combined action can contribute to PEP prevention. 
The problem with somatostatin is that it has a short 
half-life and has to be continuously administered 
intravenously. Due to those disadvantages, oc-
treotide, a somatostatin analogue is used. It 
has a half-life of 3 h, and can be administered 
subcutaneously. Arcidiacono et al[20] conducted a 
study on 151 patients who were randomly divided 
into two groups. Group A (75 patients) was given 0.1 
mg of octreotide subcutaneously 120 and 30 min 
before and 4 h after endoscopy, while group B (76 
patients) was given a placebo (1 mL of saline).
They measured serum amylase levels before 
octreotide administration and 4, 24 and 48 h after 
ERCP. Group B had a greater rise in serum amylase 
levels, but the statistically significant difference was 
measured only 48 h after ERCP. Both groups had five 
cases of pancreatitis and two cases of cholangitis. 
Overall, octreotide administration showed no 
advantages in the prevention of PEP. On the other 
hand, octreotide contributed to less severe cases 
of pancreatitis in the treated group, although the 
difference was not statistically significant. Further 
research should be conducted, especially on high 
risk patients.
In relation with somatostatin, a randomized, 
prospective, double blinded trial was conducted 
by Katsinelos et al[21] on a total number of 540 
patients divided into group A and group B in order 
to see the potential benefits of administering a 
combination of somatostatin and diclofenac sodium 
in the prevention of PEP. Both groups had the same 
number of patients, patients in group A received 
1.5 mg of somatostatin intravenously diluted in 500 
mL of saline solution 30 min before and 6 h after 
ERCP. They also received a suppository of 100 mg 
diclofenac sodium 30-60 min prior to ERCP. Patients 
in group B received 500 mL of saline and placebo 
suppositories which were same in appearance as 
diclofenac sodium suppositories. Patients who had 
complications or adverse reactions during ERCP, 
such as hypotension, intolerance to somatostatin 
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both known and confirmed risk factors for PEP. 
Furthermore, ERCP was performed by experienced 
endoscopists, which contributes to lower rates of 
PEP.
The protease inhibitors gabexate mesilate, 
ulinastatin and nafamostat mesilate have been 
registered for the treatment of acute pancreatitis. 
The rationale for their usage is a reduction in 
the pancreatic secretion of proteolytic enzymes. 
Gabexate mesilate has been shown to decrease 
the incidence of PEP[22,23], but this agent has to be 
infused continuously for as long as 13 h because 
of its short half-life; ulinastatin can be injected as 
a bolus. Furthermore, Masci et al[23] compared two 
infusion rates of gabexate mesilate; 13 h infusion 
and 6.5 h infusion. They found no difference in 
efficacy between the two infusion rates. In a recent 
meta-analysis by Yuhara et al[24], only nafamostat 
mesilate and NSAIDs showed the potential to reduce 
PEP, while the other two protease inhibitors were, 
gabexate mesilate and ulinastatin were shown 
not to be efficient in reduction of PEP incidence. 
Due to their high price and inconvenient route 
of administration, protease inhibitors cannot be 
recommended as a routine prophylactic measure. 
Positive results from Japanese trials should be 
replicated at other centers.
Non-steroidal anti-inflammatory drugs 
In some previous studies, it has been pointed out 
that phospholipase A2 has a pivotal role in the 
initial inflammatory cascade in acute pancreatitis by 
regulating a variety of proinflammatory mediators, 
including arachidonic acid products and platelet-
activating factors[25-27]. Murray et al[28] was the 
first one who described the potential of NSAIDs in 
preventing PEP. These results have been confirmed 
in several other trials[7,29-32]. Cheon et al[29] showed 
no difference between oral administration of di-
clofenac and placebo. They conducted a study on 
207 patients, 72% of whom were high risk pati-
ents (suspected SOD or pancreatic therapy). This 
suggests that rectal administration of diclofenac 
has advantages over oral administration. Katsinelos 
et al[21] concluded that a combination of diclofenac 
and somatostatin significantly lowers the incidence 
of PEP, especially in high risk patients. Univariate 
and multivariate analyses confirmed that pre-proce-
dure administration of the mentioned combination 
is associated with a significantly reduced risk of PEP. 
They also found no relevant adverse effects of these 
medications, especially no increases in bleeding after 
sphincterotomy.
There is more evidence supporting the admi-
nistration of NSAIDs. Elmunzer et al[30] performed 
a meta-analysis of studies which investigated the 
efficacy of NSAIDs on the prophylaxis of PEP. They 
analyzed four studies by Murray et al[28], Khoshbaten 
et al[31], Sotoudehmanesh et al[16] and Montãno 
Loza et al[33]. First two studies compared rectal 
administration of 100 mg of diclofenac with placebo, 
while the latter two compared rectal administration 
of 100 mg of indomethacin with placebo. Sotou-
dehmanesh et al[32] conducted a trial on 442 patients 
who were given either indomethacin or placebo 
just before ERCP. Overall, the PEP incidence was 
4.9%, which could be explained by the fact that 
only 10% of the patients in this trial had SOD. There 
was no significant difference in the PEP incidence 
between the placebo group and the indomethacin 
group, i.e., 3.2% (7/221) and 6.8% (15/221), 
respectively. However, an additional analysis found 
that indomethacin had a beneficial effect in patients 
undergoing pancreatic duct injection. The same 
group conducted an interesting trial where they 
compared indomethacin plus sublingual nitrates 
vs indomethacin alone. They reported a further 
reduction in PEP incidence in the combined group 
(indomethacin plus nitrates), i.e., RR = 0.39 and 
95%CI: 0.18-0.86, which may be of particular 
interest in high risk patients[16]. None of those 
patients developed moderate or severe pancreatitis, 
unlike the seven patients in the placebo group who 
had developed both modalities. Montãno Loza et 
al[33] conducted the same test with indomethacin and 
placebo. Their findings were different, and suggested 
a statistically significant difference in PEP incidence; 
5.3% in the indomethacin group and 16% in the 
placebo group. Murray et al[28] and Khohsbaten et 
al[31] conducted research as mentioned previously. 
They found that the incidence of PEP in the placebo 
group was higher, making the difference between 
the two groups statistically significant. Murray et 
al[28] reported a PEP incidence of 6.4% and 15.5% 
in the diclofenac and placebo groups, respectively, 
while Khoshbaten et al[31] reported a PEP incidence of 
15% in the diclofenac group and 26% in the placebo 
group. No adverse effects were noted in this meta-
analysis. Elmunzer et al[30] concluded that patients 
who received NSAIDs were 64% less likely to 
develop pancreatitis and 90% less likely to develop 
moderate to severe pancreatitis. Both diclofenac and 
indomethacin have been proven to be effective in 
preventing the development of moderate or severe 
PEP. All of the four studies that were included in this 
meta-analysis show a positive trend for prophylactic 
use of NSAIDs.
Furthermore, these studies showed that using 
NSAIDs is more cost effective. If an institution 
performs 750 ERCPs annually, and the incidence 
rate of PEP is 5%, we come to a number of 38 PEPs 
per year. United States Medicare provides financial 
support for PEP in the amount of 5700 USD per 
case, which when multiplied by the number of PEPs 
comes to 216600 USD per year. The cost of one 
dose of NSAIDs is between 1.25 and 2 USD. The 
annual cost of administering diclofenac before every 
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ERCP would be around 1500 USD, but it would 
reduce the number of PEPs to 13. Thus, a lower 
number of PEPs equals a smaller amount of money 
spent annually; we come to a figure of 74100 USD 
per PEP. Adding the cost of NSAIDs (1500 USD), 
the institution would spend 76500 USD, or 141000 
USD less than if they were not using NSAIDs. Their 
meta-analysis supports the use of NSAIDs in PEP 
prophylaxis, giving an advantage to diclofenac.
Elmunzer et al[7] conducted an additional trial 
concerning the rectal application of NSAIDs. They 
performed a multicenter, randomized, placebo-
controlled, double-blind clinical trial including 602 
patients with a high risk of PEP development. A high 
risk for PEP was established based on previously 
validated patient-related and procedure-related risk 
factors. Out of the total number of patients, 493 
(82%) had a suspicion of SOD. Patients were divided 
into two groups: one received a single dose of 
indomethacin rectally (295 patients) and the other 
received placebo (307 patients). PEP occurred in 27 
patients (9.2%) in the indomethacin group and in 52 
patients (16.9%) in the placebo group (P = 0.005). 
Furthermore, moderate/severe PEP was observed 
in 13 patients (4.4%) in the indomethacin group 
and in 27 patients (8.8%) in the placebo group (P 
= 0.03). They concluded that rectal administration 
of indomethacin notably reduced the incidence 
of PEP in patients who were at a high risk of PEP 
development. At the moment, it is absolutely clear 
that rectal administration of NSAIDs (diclofenac 
sodium and indomethacin) is the preferred method 
for reducing the incidence of PEP. Due to their good 
safety profile, low price and easy availability, NSAIDs 
are at this moment the best pharmacological 
prophylactic method. In the future, we are expecting 
the results from more randomized controlled trials 
regarding combination therapy (NSAIDs plus nitrates 
or antibiotics) and possible further reductions in the 
incidence of PEP.
Antibiotics
Prophylactic use of antibiotics is recommended by 
the British Society of Gastroenterology during ERCP 
in patients who are expected to obtain full patency 
of the bile duct, patients with advanced hematologic 
cancer, history of liver transplantation, pancreatic 
pseudocyst and patients with severe neutropenia. 
Others recommend antibiotic prophylaxis before 
ERCP, especially in the presence of biliary ob-
struction. Antibiotics should decrease or prevent 
post-ERCP complications, such as cholangitis, 
cholecystitis, septicemia and pancreatitis. A meta-
analysis was conducted by Brand et al[34] on nine 
randomized, controlled trials including 1573 patients. 
They showed the beneficial properties of antibiotic 
prophylaxis, but only in patients whose biliary 
obstruction persisted after ERCP. In patients whose 
biliary obstruction was resolved, antibiotics did not 
have much effect. The conclusion was drawn that, 
although antibiotics show beneficial properties in 
PEP prophylaxis, the presence or absence of biliary 
obstruction after ERCP is the determining factor in 
the efficacy of antibiotics and the incidence of post-
ERCP infections.
Antibiotic prophylaxis of PEP is still to be proven 
and established and there are conflicting viewpoints 
on this matter. For instance, the American Society 
for Gastrointestinal Endoscopy recommends anti-
biotic prophylaxis for ERCP in patients with bile duct 
obstruction.
Research performed by Räty et al[35] suggests 
that antibiotic prophylaxis effectively decreases the 
risk of PEP development. They conducted a study on 
321 patients, who were divided into two groups: a 
prophylaxis group and a control group. There were 
161 patients in the prophylaxis group; all received 
2 g of cephtazidime, and 160 patients in the control 
group who did not receive an antibiotic. Patients 
with allergy to cephalosporins, immunodeficiency, 
clinical jaundice or with any other condition requiring 
antibiotic usage were excluded. Also, pregnant 
patients did not participate. The diagnosis of acute 
pancreatitis was based on increased levels of 
serum amylase (> 900 IU/L), CRP level, leukocyte 
count, no increase in liver chemical values and 
clinical findings. Nine patients in the prophylaxis 
group (6%) and 15 patients in the control group 
(9%) had a notable increase in serum amylase 
levels (> 900 U/L) after ERCP, but only four out of 
nine patients in the prophylactic group developed 
clinical signs of pancreatitis, leukocytosis and pain. 
In comparison, all 15 patients from the control 
group with hyperamylasemia had pain, elevated 
CRP, leukocytosis and other signs of pancreatitis. 
Multivariate analysis showed that lack of antibiotic 
prophylaxis and sphincterotomy are independent 
risk factors for the development of PEP. They 
concluded that the application of antibiotics as 
chemoprophylaxis effectively decreases the chances 
of PEP development.
However, in the most extensive review and meta-
analysis by Bai et al[36] on antibiotic prophylaxis of 
post-ERCP cholangitis, the authors included seven 
trials and 1389 patients which were divided into two 
groups: 705 patients in the control group and 684 in 
the treated group. Cholangitis occurred in 5.8% of 
control group patients and 3.4% of treated patients, 
with no statistical significance. In accordance with 
the ASGE recommendations for antibiotic pro-
phylaxis, sensitivity analysis was performed tar-
geting patients with suspicious biliary obstruction. It 
showed that the incidence of post-ERCP cholangitis 
was 2.8% in patients who received antibiotics and 
5.4% in control group patients, suggesting that 
there is no protective effect of antibiotics. In their 
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summary, they agreed that antibiotics cannot be 
used as an effective means of post-ERCP cholangitis 
prevention.
Although their data showed no correlation be-
tween antibiotic prophylaxis and a reduced rate of 
post-ERCP cholangitis, we can assume that the same 
premise can be applied to the connection of antibiotic 
prophylaxis and PEP prevention, i.e., antibiotic 
administration will not be effective in the prophylaxis 
of PEP. However, due to the lack of sufficient data on 
this topic, we believe that further research should 
be conducted in an attempt to show the potential 
benefit of antibiotics as chemoprophylactic agents.
Other pharmacological treatments
There are some other pharmacological agents th-
ought to be potentially beneficial in PEP prophylaxis. 
For example, allopurinol has demonstrated beneficial 
properties in animal models. However, three trials 
with human subjects offer conflicting and inconclusive 
results[37,38]. In two trials, the authors showed benefits 
from the usage of allopurinol. Kastinelos et al[37] gave 
600 mg of allopurinol per os to their patients 15 and 
3 h before ERCP and saw significantly lower rates 
of PEP in comparison to the placebo group; 3.2% 
and 17.8%, respectively. Furthermore, patients with 
pancreatitis who received allopurinol had shorter 
duration of hospital stay than those who were in 
the placebo group. Martinez-Torres et al[38] gave 
300 mg of allopurinol per os to 85 patients at same 
times as in the Katsinelos trial, while the other 
85 patients received oral placebo. They observed 
significantly lower rates in PEP incidence, i.e., 
2.3% in comparison to 9.4% in the placebo group. 
However, Mosler et al[39] conducted a trial where they 
randomly administered allopurinol and placebo 4 h 
and 1 h prior to ERCP. PEP incidence was 12.96% 
and 12.14%, in allopurinol and placebo groups, 
respectively. They concluded that there is no efficacy 
of allopurinol prophylaxis of PEP.
A new possible treatment to the prevention 
of PEP is being used by German physicians who 
recently published a study protocol[40]. They designed 
a randomized, double-blind, placebo controlled 
study where they will test the effect of magnesium 
sulfate on the incidence and severity of PEP. They 
will include a total of 502 patients distributed into 
two groups. One group of patients will receive 4930 
mg of magnesium sulfate 60 min before and 6 h 
after ERCP and the other group will receive placebo 
at the same time intervals. The incidence of PEP and 
hyperlipasemia, the degree of pain, analgesic usage 
and the length of hospitalization will be observed 
and analyzed. Their opinion is that, if successful, 
magnesium sulfate could become a routinely used a 
pharmacological prophylactic agent.
There are some alternative approaches with 
promising results such as aggressive hydration with 
Ringer’s lactate[41,42]. Buxbaum et al[41] performed a 
study in which patients who were undergoing ERCP 
for the first time were randomly assigned to groups 
(2:1) that either received aggressive hydration 
with lactated Ringer’s solution (3 mL/kg per hour 
during the procedure, a 20-mL/kg bolus after the 
procedure, and 3 mL/kg per hour continuously for 
8 h post-ERCP) or standard hydration with Ringer’s 
solution (1.5 mL/kg per hour during and for 8 h 
post-procedure). They concluded that aggressive 
intravenous hydration with lactated Ringer’s solution 
reduces development of PEP. Since these are the 
results of a pilot study with only 62 patients, this 
benefit has to be shown in trials with an adequate 
sample size.
Although we have adequate pharmacological 
agents such as NSAIDs, which can significantly 
reduce the incidence of PEP, possible new approa-
ches are very welcome. We are eager to see the 
results from adequately powered trials regarding 
aggressive hydration. If we get positive results, this 
may become the easiest preventive method.
Non-pharmacological approaches
Vila et al[43] presented an article reviewing the 
factors contributing to PEP and other post-ERCP 
complications, such as non-technical factors and 
technical factors. They also emphasized the role of 
pancreatic stenting and NSAIDs in PEP prophylaxis 
as the two methods with the most scientific 
evidence. Non-technical factors include placement of 
the pancreatic stent and administration of NSAIDs. 
Multiple studies have shown the benefits of placing a 
pancreatic stent.
Pancreatic stent placement
There are many reviews and analyses suggesting 
the beneficial impact of pancreatic stent placement. 
Singh et al[44] conducted a meta-analysis which 
included five studies and 481 patients. They showed 
that the incidence of PEP in the stented group was 
significantly lower (5.8%) in contrast to the no-
stent group (15.5%).They drew a conclusion stating 
that temporary placement of a stent in the main 
pancreatic duct lowers risk for PEP. Additional meta-
analysis of one more study by Andriulli et al[45] 
showed similar results. They conducted a meta-
analysis of 6 controlled studies with an addition of 
12 uncontrolled studies. Their results showed that 
the stented group had a PEP rate of 12% while the 
control group rate was 24.1%. They also showed 
a reduction in the number of cases of severe 
pancreatitis in stented patients. Choudhary et al[46] 
conducted a meta-analysis on eight randomized, 
controlled trials and 656 patients, and 10 non-
randomized studies including 4904 patients. They 
observed the incidence of PEP, incidence of hy-
peramylasemia, incidence of mild, moderate and 
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severe pancreatitis, and possible adverse effects 
of stent placement. The results of the randomized, 
controlled studies showed a significant decrease 
in the PEP incidence in the stented group, i.e., 
4.6%. The incidence of PEP in the control group 
was 19.7%. Furthermore, fewer PEP cases were 
observed in patients with a stent < 3 cm, but with 
no statistical significance. No statistically significant 
difference was noted in using flanged and unflanged 
stents. Concerning hyperamylasemia, levels were 
significantly lower in the stented group. Analysis of 
the non-randomized trials also showed a statistically 
significant lower incidence of PEP in five trials. 
Moreover, pancreatic stenting led to fewer cases of 
severe pancreatitis. Although there is no doubt that 
pancreatic stents decrease the incidence of PEP, 
several questions remains unanswered, possibly vital 
questions which if answered could lower the PEP 
incidence even more. Who should get a pancreatic 
stent? What is the best time of placement - before 
or after therapy, e.g., before sphincterotomy? How 
long do stents have to remain in place? For now, 
pancreatic stents are placed in high risk patients. 
Further research has to be done in order to provide 
answers to these questions. However, the European 
Society of Gastrointestinal Endoscopy recommends 
stent placement in high risk patients undergoing 
ERCP[2]. High risk patients are, according to a 
consensus, patients with SOD, young women, 
patients with previous pancreatitis, and patients 
with a high number of cannulations and injections 
of the pancreatic duct during ampullectomy or 
cannulation. The recommended size of the stent 
is 5-Fr. Furthermore, pancreatic stents should be 
placed taking endoscopists’s rate of success into 
consideration, which has to be > 75%[2].
Mazaki et al[9] reviewed and conducted a meta-
analysis on 8 studies including 680 patients. 
All studies included different kinds of high risk 
patients, such as SOD, difficult cannulation, precut 
sphincterotomy, biliary balloon dilatation of an 
intact papilla for stone extraction, ampullectomy 
or pancreatic brush cytology. Pancreatic stent 
placement had a success rate of 90% to 100% in 
five studies. Out of the total number of 680 patients, 
336 received a pancreatic stent, while 344 were in 
the control group. Total number of PEPs was 82; 19 
patients (6%) in the stent group, and 64 patients 
(19%) in the control group, which was statistically 
significant. They also showed that pancreatic stents 
were more efficient in high risk patients. This meta-
analysis showed that pancreatic stent placement is a 
good and effective prophylaxis for PEP. Furthermore, 
it is consistent with previously performed meta-
analyses[44,45].
Ito et al[47] conducted a study on 9192 ERCP 
procedures. Out of the total number of ERCPs, 
414 patients were included in this study as they 
were high risk patients for the development of 
PEP. High risk criteria were: female gender, history 
of pancreatitis, SOD, difficult cannulation of the 
bile duct, pancreatic duct cytology/biopsy, precut 
sphincterotomy, pancreatic sphincterotomy and 
endoscopic ampullectomy. The size of stents used 
was 5-Fr, 3 cm long with a single pigtail. The goals 
of this study were to explore the frequency and 
severity of PEP, the frequency of hyperamylasemia 
and risk factors for PEP. The incidence of PEP was 
9.9% and 90% of those were mild cases. Taking the 
high risk factors of these patients into consideration, 
the PEP incidence in this study was acceptable. The 
frequency of moderate to severe cases of PEP was 
10%. In two important studies[48,49], the rates of 
moderate and severe pancreatitis were 47% and 
25%, respectively. In conclusion, the results of 
this study suggested that pancreatic duct stenting 
decreases the incidence of PEP, and could possibly 
contribute to less severe cases of PEP, thereby 
easing the patient’s recovery.
Zolotarevsky et al[50] conducted a trial regarding 
the optimal stent size for insertion into the pan-
creatic duct for PEP prevention. The current view-
point on stent size goes in favor of 5-Fr stents. 
Zolotarevsky et al[50] compared 5-Fr and 3-Fr stents 
in order to see which one led to better results in 
pancreatic stenting. A large trial by Rashdan et al[51] 
was conducted on 2283 patients who underwent 
ERCP and had a 3-4-Fr, unflanged stent placed. 
Incidence of pancreatitis was 7.5% and 10.6% for 
3-Fr and 4-Fr stents, respectively in comparison 
with rates of 9.8% and 14.6% for larger stents, 
5-Fr and 6-Fr, respectively. They concluded that 
smaller sized stents were superior to larger ones in 
preventing PEP. However, Chahal et al[52] showed a 
completely different situation; 5-Fr stents correlated 
with higher rates of spontaneous stent passage and 
lower rates of PEP. In addition, this study showed 
that placing 3-Fr stents had more failed attempts. 
Failure in placing a stent can prolong the procedure 
and thus augment the chances of PEP development. 
A comparison of 5-Fr and 3-Fr stents done by 
Zolotarevsky et al[50] was performed on 234 patients 
by random assignment of those stents. Out of the 
total number of patients, 78 were at high risk for 
PEP. Pancreatic stent placement was successful in 77 
patients. Spontaneous passage rates duringa two-
week period were 68.4% and 75% for the 5-Fr and 
3-Fr stents, respectively. Lack of stent passage at 2 
wk was also nearly the same, i.e., 10.5% and 10% 
for the 5-Fr and 3-Fr stents, respectively.
Another important aspect in comparison of 
these two stents and their efficacy was the number 
of wires needed for stent placement. One wire 
was sufficient in 22 cases of 5-Fr stent placement 
(59.4%), whereas 3-Fr stent placement with 
one wire occurred in only eight cases (20.5%); a 
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significant difference. The time required to place 
a stent was more frequently prolonged during 
the placement of 3-Fr stents. Furthermore, the 
placement of 5-Fr stents was deemed easier than 
placing a 3-Fr stent.
Eleven patients (14.1%) developed PEP, which 
manifested a sa mild or moderate form. There 
was no statistically significant difference in PEP 
incidence between the stent groups. In conclusion, 
an increased number of wires needed for successful 
stent placement, prolonged attempts for stent 
placement and a higher number of failed stenting 
attempts may be associated with a higher incidence 
of PEP. In this study, the results showed that the 
technical aspects of the 5-Fr stent render it favorable 
over the 3-Fr stent; its placement is easier, faster 
and requires fewer wires. These criteria alone should 
be enough to give the 5-Fr stent an advantage in 
choosing the better and more effective stent in 
pancreatic stent placement. A recent, excellent 
network meta-analysis has provided definite results 
regarding some of these dilemmas. Afghani et al[53] 
analyzed 6 randomized, controlled studies including 
561 patients. The authors concluded that the 5-Fr 
stent is superior to the 3-Fr pancreatic stent for the 
prevention of PEP in high risk patients. Also, the 
performance of 5 Fr stents was not influenced by the 
design (flanged, straight, pigtail), suggesting that 
the diameter is more important for the prevention of 
PEP than the type of stent.
Despite the robust data which favor the usage of 
NSAIDs and pancreas stenting in the prevention of PEP, 
gastroenterologists still have some doubts. Dumonceau 
et al[54] completed a survey about prophylactic 
pancreatic stenting and NSAID administration. They 
distributed the survey to 467 medical doctors, but 
collected only 141 completed ones. The majority 
of respondents (61.7%) worked in a community 
hospital where the ERCP volume was ≤ 500 per 
year. Diagnostic ERCP was used in < 20% of cases 
by the majority of respondents (83%). The majority 
of the respondents did not attempt prophylactic 
pancreatic stenting in the presence of procedure-
related risks for PEP, such as prolonged or difficult 
cannulation, previous PEP or needle pre-cut. Only 
in the case of ampullectomy did the majority of 
respondents (54.5%) attempt pancreatic stenting. 
They attempted the procedure in more than 50% of 
cases. However, pancreatic stenting was attempted 
more frequently when patient-related risk factors 
were present. Thirty respondents (21.3%) did 
not attempt pancreatic stenting at all. Those who 
attempted pancreatic stenting used mainly 5-Fr 
stents (64.5%). Fourteen of them used either 3-Fr 
or 7-Fr stents. The majority of respondents, namely 
118 of them (83.7%) did not use NSAIDs for PEP 
prevention; 88.1% of those 118 respondents cited 
lack of evidence as the main reason.
This survey showed a huge gap between the 
scientific evidence supporting prophylactic pancreatic 
stenting and its actual application in practice. The 
reasons for this are a lack of experience and the 
difficulty of the procedure itself (pancreatic stenting 
has the highest degree of difficulty). Many of the 
respondents have little or no confidence in using 
NSAIDs due to the lack of supporting evidence. 
Further investigations into PEP prophylaxis and 
better and more frequent ERCP education could 
provide a more stable ground for the implementation 
of techniques and increasing knowledge of the 
prevention of PEP.
Cannulation
Other technical factors include techniques used in 
duct cannulation, sphincterotomy and ampullectomy. 
Guide wire cannulation is one of these factors, and 
there are many variations. Guide-wire hovering is a 
variation of direct cannulation where the guide wire 
hovers a few millimeters to a couple of centimeters 
through the catheter or sphincterotome. It is useful 
in pancreatic cannulation when access through the 
minor papilla is needed.
The guide wire technique has advantages in 
comparison to contrast cannulation. For example, 
Cennamo et al[55] conducted a meta-analysis of five 
randomized controlled studies with 1762 patients 
who showed that guide wire cannulation improves 
the cannulation rate from 74.9% to 85.3% and, 
more importantly, reduces the incidence of PEP 
from 8.6% to 1.6%. Subsequently, guide wire can-
nulation is considered to be the standard for can-
nulation. Another variation is pancreatic stenting 
after guide wire placement. Fogel et al[56] reported a 
significant difference in the incidence of PEP between 
pancreatic stent placement followed by needle-knife 
sphincterotomy and double wire cannulation. Placing 
a stent led to a PEP incidence of 10.7%, while the 
double wire technique had a rate of 28.3%. Madacsy 
et al[57] also showed the benefits of stent placement. 
There were no cases of PEP in stented patients, 
while the PEP incidence in patients who underwent 
needle-knife with guide wire cannulation was 43%.
It is well known that pre-cut sphincterotomy 
increases the rate of PEP. It is still not well-defined 
regarding what is the best approach: to persistently 
attempt to cannulate or an early (five to ten minutes) 
switch to pre-cut. A meta-analysis by Cennamo et 
al[58] analyzed six trials by comparing the rates of 
cannulation and the incidence of PEP in early pre-cut 
cannulation and persistent cannulation with a late 
pre-cut. The analyzed data showed no difference 
in the success rate, i.e., 90.2% and 89.6%, res-
pectively. However, the incidence of PEP differed 
significantly. PEP occurred in 2.48% in early pre-cut, 
while its rate was 5.34% in late pre-cut. Another 
meta-analysis by Gong et al[59] also suggests that 
early pre-cut is more beneficial in PEP prophylaxis. 
Debate is still ongoing because two recent meta-
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analyses have not provided a consistent answer[60,61]. 
While one group suggests that the rates of PEP 
are similar in the pre-cut sphincterotomy group 
and in the persistent attempt group (OR = 0.58, 
95%CI: 0.32-1.05)[61], in the other meta-analysis, 
the authors claimed to have concluded that the 
early pre-cut technique decreases the trend of PEP 
incidence[60]. According to the recent literature, 
we may conclude that we have an obvious trend 
towards a reduction in PEP incidence by adopting the 
early pre-cut approach, but further data are needed.
While it is obvious that the wire-guide cannulation 
technique and pancreatic duct stenting significantly 
reduce PEP incidence, we are still lacking data 
regarding the early pre-cut technique. Endoscopists 
have dilemmas about continuing with attempts to 
cannulate and possibly further traumatizing the 
papilla, which can hamper cannulation later on, or 
switch to the needle knife early but possibly increase 
the risk of PEP, bleeding or perforation. With une-
quivocally positive results regarding early pre-cut, 
our decision would be easier.
CONCLUSION
In summarizing the prophylactic measures against 
PEP, we can conclude that only two methods of 
prophylaxis are currently recommended: pancreatic 
stent placement and NSAID administration, preferably 
with diclofenac.
Pancreatic stent placement is a recommended 
and effective method for preventing PEP today. 
Much is known of its beneficial properties, the type 
of stent needed, the duration of stent placement 
and so on. It is a method which has been proven to 
be effective. NSAIDs are cheap, can be easily given 
to patients and have little or negligible adverse 
effects, making diclofenac and other NSAIDs an 
attractive approach in PEP prevention, but there is 
still resistance to its usage due to the lack of reliable 
supporting evidence and/or the lack of information.
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